MediBloc
MED - # 573 ActiveKorean Asset
-
Rating Score 51.08Rating Grade C+
- Rating Version APYWA-v1.1 / Rating Date 2025-12-22
Overview
MediBloc (MED) is a blockchain-based digital asset designed to support the integrated management and secure sharing of medical data. MediBloc builds a patient-centric healthcare data ecosystem that enables individuals to own and manage their medical data while securely sharing it with healthcare providers and researchers. The native token, MED, is used within the platform for purposes such as data transactions, payment of gas fees, and providing incentives. MediBloc aims to improve the efficiency of healthcare services while enhancing the transparency and security of medical data, ultimately supporting the development of a personalized healthcare ecosystem.
Metric Radar Chart
Metric Bar Chart
Metric Trends
| Total Rating Score | TNNeutral |
|---|---|
| Market Accessibility | TNNeutral |
| Development Activity | TNNeutral |
| Market Liquidity | TNNeutral |
| Community Engagement | TNNeutral |
| Risk & Security | TNNeutral |
Total Rating Score Trend
Market Data
- Token Price $0.002483 (↘1.82%)
- Volume (24h) $1.18M (↗218.69%)
- Market Cap $26.43M (↗2.07%)
-
Circulating Supply
10,644,041,819 MED
10,644,041,819 MED
(Source : Coinmarketcap , Coingecko )
Listed Exchanges
- Korean
-
- Global
-
×
View All Exchanges
- Korean
-
- Global
-
Community Info
X (Twitter) Tweets (Last 30 Days)
- (-)
Development Info
-
GitHub Account
Medibloc
-
Stars
283 (-)
- Commits (Last 3 Months) 0 (-)
Security Audit Info
- Security Audit Status None
- CertiK Code Security Score 78 pts
(Source : Coinmarketcap , CertiK Skynet )
Issue Info
- Trading History
- No records found
- Risk History
- No records found
View Full History
| Category | Date | Exchange | Link | Grade | Details |
|---|---|---|---|---|---|
| Regular Evaluation | 2025-01-06 | - | - | C+(51.45) | [AW-0019-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-01-02 | - | - | C(49.35) | [AW-0018-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-12-30 | - | - | C+(50.67) | [AW-0017-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-12-26 | - | - | C+(51.09) | [AW-0016-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-12-23 | - | - | C+(53.13) | [AW-0015-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-12-19 | - | - | C+(52.17) | [AW-0014-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-12-16 | - | - | B-(55.11) | [AW-0013-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-12-12 | - | - | C+(52.17) | [AW-0012-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-12-09 | - | - | C+(52.37) | [AW-0011-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2024-12-05 | - | - | B-(55.49) | [AW-0010-정기] 평가가 완료되었습니다. |
- Disclaimer
-
The ratings provided by APYWA (hereinafter 'the Company') are conducted via an automated system based on public data and are pure data-driven analysis results with no subjective elements. This rating material includes evaluations on five key metrics: Market Accessibility, Development Activity, Market Liquidity, Community Engagement, and Security. All information provided is for reference purposes only.
Our ratings are not intended as investment advice or recommendations, and we do not guarantee the accuracy, completeness, or timeliness of the information. Users must make their own investment decisions based on the provided data, and the Company bears no legal liability for any resulting losses or damages.
While the rating material is processed automatically based on reliable data, discrepancies with actual market conditions may occur due to data limitations. Therefore, the Company is not liable for any damages arising from the use of the provided information. All information contained herein is the property of the Company and may not be reproduced, distributed, or modified without prior approval.